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Versatile microscale screening 
platform for improving 
recombinant protein productivity in 
Chinese hamster ovary cells
Henning Gram Hansen1, Claes Nymand Nilsson1, Anne Mathilde Lund2, Stefan Kol1, 
Lise Marie Grav1, Magnus Lundqvist3, Johan Rockberg3, Gyun Min Lee1,4, 
Mikael Rørdam Andersen2 & Helene Faustrup Kildegaard1
Chinese hamster ovary (CHO) cells are widely used as cell factories for the production of 
biopharmaceuticals. In contrast to the highly optimized production processes for monoclonal antibody 
(mAb)-based biopharmaceuticals, improving productivity of non-mAb therapeutic glycoproteins is 
more likely to reduce production costs significantly. The aim of this study was to establish a versatile 
target gene screening platform for improving productivity for primarily non-mAb glycoproteins 
with complete interchangeability of model proteins and target genes using transient expression. 
The platform consists of four techniques compatible with 96-well microplates: lipid-based transient 
transfection, cell cultivation in microplates, cell counting and antibody-independent product titer 
determination based on split-GFP complementation. We were able to demonstrate growth profiles and 
volumetric productivity of CHO cells in 96-half-deepwell microplates comparable with those obtained 
in shake flasks. In addition, we demonstrate that split-GFP complementation can be used to accurately 
measure relative titers of therapeutic glycoproteins. Using this platform, we were able to detect target 
gene-specific increase in titer and specific productivity of two non-mAb glycoproteins. In conclusion, the 
platform provides a novel miniaturized and parallelisable solution for screening target genes and holds 
the potential to unravel genes that can enhance the secretory capacity of CHO cells.
The production of recombinant therapeutic proteins is a rapidly growing industry with a global sales value of 
approximately $140 billion in 20131. The main production host of biopharmaceuticals is Chinese hamster ovary 
(CHO) cells2, the productivity of which has improved substantially since the mid-1980s with focus on media 
composition and bioprocess design3,4. Production of therapeutic monoclonal antibodies (mAbs) in CHO cells in 
optimized bioprocesses typically reaches 5 g/L titers5 and specific productivity (qp) of 50–90 pg per cell per day 
(pcd)3 resulting in production costs accounting for only 1 to 5% of the sales price5. However, significantly lower 
titers and qp are more common for glycosylated non-mAb biopharmaceuticals5,6. Thus, increasing titer and qp for 
non-mAb glycoproteins holds the potential to reduce production costs significantly.
Genetic engineering of CHO host cells is a well-established method for improving productivity by enhancing 
cell survival and qp or increasing cell growth and qp7. Several studies have demonstrated positive effects of overex-
pressing genes on productivity of recombinant glycoproteins in CHO cells (for reviews see7,8). However, contradic-
tory effects on qp have been reported for some genes8,9. These discrepancies are likely a combined effect of multiple 
factors. For example, when working with stable clones, observed effects may be a consequence of clonal variation6,10. 
Moreover, the effects of ectopic expression of recombinant genes likely depend on physicochemical characteristics 
of the therapeutic glycoprotein9. A transient transfection-based overexpression screening platform has the potential 
to address these issues, because it enables complete interchangeability of which genes (hereafter referred to as target 
genes) and model therapeutic glycoproteins (hereafter referred to as model proteins) to express. Furthermore, clonal 
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variation is not an issue when a pool of transfected cells are analysed6. Generic antibody-independent product titer 
determination methods would facilitate complete interchangeability of model proteins because specific antibodies 
for each individual model protein would not be needed. Split-GFP complementation-based product titer assays 
provide such an antibody-independent solution11.
Recent advances in the split-GFP complementation technique have enabled a relatively small part (16 amino 
acid residues) of GFP to be tagged to the protein of interest; which is the 11th β -strand of GFP’s β -barrel (S11)11. 
The remaining part of GFP (GFP1–10; 214 amino acid residues) has been optimized for complementation and 
solubility (GFP1–10OPT)11. Separately, S11 and GFP1–10OPT are principally non-fluorescent; however, when the 
two fragments are mixed, the chromophore of GFP is formed and fluorescence complementation takes place12. 
Fluorescence intensity upon complementation is proportional to the concentration of the S11-tagged protein 
when GFP1–10OPT is in excess11, making this technique useful for product titer determination. A variant of the 
S11 peptide (M3 variant; S11_M3) was selected based on good complementation characteristics and minimal 
perturbation on solubility of tagged proteins in E. coli11. The S11_M3-tag is therefore less likely to perturb folding 
processes and solubility than previous, larger versions of the split-GFP tag13,14.
In the present study, we chose two non-mAbs as model proteins: human α 1-antitrypsin (hα 1AT) and human 
C1 esterase inhibitor (hC1INH). hα 1AT is a protein of 394 amino acid residues with three N-glycans15; hC1INH 
(478 amino acid residues) contains six N-glycans and at least seven O-glycans16. Currently, hα 1AT and hC1INH 
are not produced commercially in cultured mammalian cells but are derived from human plasma for therapeutic 
use15,17. In addition, recombinant hC1INH (RuconestTM) produced in milk of transgenic rabbits has recently been 
approved as a biopharmaceutical product18.
We set out to establish a miniaturized and parallelisable transient transfection-based screening platform to 
improve the productivity of therapeutic glycoproteins in CHO cells (Fig. 1). The platform combines four techniques 
suitable for the 96-well format: (1) Lipid-based transfection and transient overexpression (2) Cell cultivation in 
half-deepwell (HDW) microplates. (3) Fluorescence image cytometry-based cell counting. (4) Split-GFP-based 
product titer assay. We wanted to investigate the general applicability and versatility of the platform. To this end, 
we analysed the effect on productivity of hα 1AT and hC1INH of overexpressing previously published target genes 
in CHO cells. By using this screening platform, we were able to demonstrate gene-specific increase in titer and qp 
for our two model proteins.
Materials and Methods
Plasmids and primers. All primers used in this study are listed in Supplementary Table S1. The elements 
inserted into all constructs were verified by sequencing, and purified plasmid was obtained using the Nucleobond® 
Xtra Midi Kit (Machery-Nagel, Düren, Germany) according to the manufacturer’s instructions.
Plasmids encoding Rituximab and codon-optimized human Erythropoietin (hEPO) have previously been 
described19. The human genes Serpina1 and Serping1, which encode hα 1AT and hC1INH, respectively, either 
untagged or tagged with S11_M3 or S11_H7 (H7 variant of S11), were subcloned into pcDNA3.1(+ )/Zeo (for 
schematic overview see Supplementary Fig. S1a; for sequences, see Supplementary Table S2).
Solid-phase cloning (SPC)20 was used to fuse the S11_M3-tag to the C-terminus of hC1INH. pcDNA3.1(+ )/Zeo 
encoding hC1INH (PL_hC1INH_notag; Supplementary Table S3) was PCR amplified using Phusion® Hot-Start 
Flex (New England Biolabs, Ipswich, Massachusetts, USA) and primers #131 and #132. Primer #133 was designed 
to include 30 bases for hybridization, an amino acid linker (GGGSGGGS), and the S11_M3 sequence. The oligo 
Figure 1. Schematic illustration of the screening platform. (1) CHO cells are co-transfected with plasmids 
encoding target genes and plasmids encoding S11(Split-GFP)-tagged model protein. (2) Transfected cells 
are cultivated in a 96-half-deepwell microplate capped with a low-evaporation Duetz sandwich cover (cover 
not shown). (3) Viable cell density is determined using image fluorescence cytometry on Hoechst and 
propidium iodide (PI) stained cells. (4) Upon addition of GFP1–10OPT to supernatants, relative product titers of 
supernatants are determined by split-GFP complementation.
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(primer #133) was genetically coupled to the C-terminus of Serping1 by head-to-tail SPC on a Magnatrix 1200 
workstation (NorDiag AS, Oslo, Norway).
The remaining hα 1AT and hC1INH constructs (Supplementary Table S4) were cloned by seamless PCR-based 
uracil-specific excision reagent (USER) fusion cloning, essentially as previously described21, using primers designed 
by the AMUSER software22. In brief, PCR amplicons (Supplementary Table S5) were made using the proofreading 
polymerase PfuX723 and assembled by treating with USER Enzyme (New England Biolabs) and transforming into 
E. coli One Shot® Mach1™ competent cells (Life Technologies, Thermo Scientific, Rockford, IL).
All target genes were cloned into a vector harbouring an ‘Nt.BbvCI/PacI A’ USER cassette (PL_TGExpr) 
(Supplementary Fig. S1b). PL_TGExpr was made using Flexible Assembly Sequence Tag-USER-based clon-
ing (FAST-USER) as previously described24 (Supplementary Table S6). Coding sequences of target genes were 
PCR-amplified using PfuX7 polymerase and primers designed by AMUSER software (Supplementary Table S5). 
Coding sequences were inserted into the ‘Nt.BbvCI/PacI A’ USER cassette of PL_TGExpr as previously described25 
(Supplementary Table S6).
Cell cultivation. CHO-S suspension cells (Life Technologies) were grown in CD CHO medium supplemented 
with 8 mM L-glutamine and 2 μ L/mL anti-clumping agent (Life Technologies). Cells were expanded in Corning 
vent cap shake flasks (Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 120 rpm (25 mm orbit), 37 °C, 
and 5% CO2.
Transfection. Transfection in shake flasks, 6-well plates and 96-well microplates is described in Supplementary 
Information.
96-well based cell counting assay. Dye master mix was made daily: CD CHO + 8 mM L-glutamine + 5 μ g/mL 
Hoechst-33342 (Life Technologies) + 0.4 μ g/mL propidium iodide (Life Technologies). Master mix (200 μ L) and cell 
suspension (3 μ L) were mixed in a 96-well optical-bottom microplate (Greiner Bio-One, Frickenhausen, Germany) 
and cells were incubated for 40 min at RT. Image cytometry analysis was performed on a Celigo Imaging Cell 
Cytometer (Nexcelom Bioscience, MA, USA). Cells were identified using the blue channel (Hoechst-positive 
cells), and the red fluorescence channel (propidium iodide) was used to detect dead cells. Total cell density was 
computed from the total number of identified cells in the well. Cell viability was defined as the percentage of 
propidium iodide-negative cells. Based on total cell density and viability, viable cell density (VCD) was determined.
For comparison, VCD measurements were performed on a NucleoCounter NC-200 Cell Counter (ChemoMetec, 
Allerod, Denmark) using Via1-Cassettes™ using a Viability and Cell Count Assay (NucleoView software ver. 
1.1.18.1) according to the manufacturer’s instructions.
Deglycosylation of proteins. N-glycans on proteins in supernatant samples were removed by PNGase 
F treatment (New England Biolab) under denaturing conditions according to the manufacturer’s instructions. 
N-glycans and O-glycans on proteins in supernatant samples were removed using Protein Deglycosylation Mix 
(New England Biolab) under denaturing conditions according to the manufacturer’s instructions.
Western blot analysis. All samples for Western blotting were subjected to reducing SDS-PAGE on NuPAGE® 
Novex® 4–12% Bis-Tris Protein Gels (Life Technologies) in MOPS running buffer before transfer onto nitrocel-
lulose membrane using the iBlot® 2 Dry Blotting System (Life Technologies). Primary antibodies: polyclonal goat 
hα 1AT antibody (#ab7633, Abcam, Cambridge, UK) and rabbit polyclonal hC1INH antibody (#ab97348, Abcam). 
Secondary antibodies: horseradish peroxidase (HRP)-conjugated polyclonal donkey anti-goat IgG secondary 
antibody (#31458, Pierce, Thermo Scientific) and HRP-conjugated polyclonal goat anti-rabbit IgG secondary 
antibody (#ab6741, Abcam). Bound antibody was detected with ECL Prime Western Blotting Detection Reagent 
(GE Healthcare, Little Chalfont, United Kingdom).
Split-GFP product titer assay. Split-GFP product titer assay was performed essentially as described else-
where26, but with minor changes to the protocol (see Supplementary Information).
Protein quantification by ELISA and bio-layer interferometry. The hα 1AT titer in supernatant sam-
ples was determined using a hα 1AT ELISA Kit (#OKIA00048; Aviva Systems Biology, San Diego, CA, USA) 
according to the manufacturer’s instructions. The hα 1AT calibrator from the kit (lyophilized serum) was used as 
standard. The titer of hC1INH in supernatant samples was determined using a hC1INH ELISA pair set (#SEK10995; 
Sino Biological Inc., Beijing, China) according to the manufacturer’s instructions. Purified recombinant his-tagged 
hC1INH (#10995-H08H, Sino Biological) was used as standard. The titer of hEPO in supernatant samples was 
determined using a hEPO ELISA Kit (#ab119522, Abcam) according to the manufacturer’s instructions. Purified 
recombinant hEPO (#Z02975-50, GenScript, Piscataway, NJ, USA) was used as standard. The Rituximab titer in 
supernatant samples was determined by bio-layer interferometry using an Octet RED96 (ForteBio, Pall, Menlo 
Park, CA, USA) as previously described27, but with an increased shaking speed of 1000 rpm.
Calculation of productivity parameters. Integral of viable cell density (IVCD) and daily specific produc-
tion rate were calculated as described elsewhere6.
Statistical analysis. Data (fold-changes) were tested for normality by D’Augustino-Pearson omnibus 
test using GraphPad Prism software (version 6.05 for Windows, GraphPad Software, La Jolla, CA, USA). Data 
(non-transformed and log2-transformed) in some groups did not pass the normality test, so statistical significance 
(p ≤ 0.05) was assessed by performing the Mann-Whitney nonparametric test (two-tailed) on non-transformed 
fold-changes using GraphPad Prism software.
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Results
Establishment of a 96-well-based cell-counting assay. In order to monitor cell growth in 96-well 
microplates, we wanted to use a 96-well-based cell-counting assay compatible with small sample volumes. Based 
on a study by He and co-workers28, we established an assay that combines viability stain and 96-well-based imaging 
cell cytometry using 3 μ L cell culture per sample (Fig. 1). Hoechst stain was used to identify the total number of 
cells (dead and alive) and propidium iodide stain was used to identify dead cells.
Overall, VCD measurements of the 96-well-based assay were consistent with results obtained with the commer-
cially available acridine orange- and DAPI-based NucleoCounter NC-200 Cell Counter (Fig. 2a,b). For analysis 
by the NucleoCounter NC-200 Cell Counter, dilution of cell cultures in which VCD exceeds 5 × 106 cells/mL 
Figure 2. Wide linear range and low variation in 96-well-based cell counting assay. Comparison of 
NucleoCounter® NC-200 and 96-well-based (combined Hoechst and propidium iodide stain) cell-counting 
assay (eight technical replicates). (a–d) A dilution series of exponentially growing healthy CHO-S cells was 
analyzed. (a) Viable cell density (VCD) is plotted against relative cell concentration. Black rectangles and red 
circles denote data points from 96-well-based cell-counting and NucleoCounter assay, respectively. Mean and 
standard deviation are depicted. The dashed black line and solid red line show trend lines from linear regression 
of 96-well-based cell-counting (R2 = 0.999) and the NucleoCounter assay (R2 = 0.998), respectively. The 
encircled data point was found to be an outlier in the linear regression analysis. (b) Zoomed view of the graph 
shown in panel (a). (c) Coefficient of variation (CV) of VCD measurements at different cell concentrations. 
The x-axis denotes relative cell concentration and VCD values in brackets (× 105 cells/mL). White and grey bars 
denote the NucleoCounter and 96-well-based cell-counting assay, respectively. (d) Viability at different cell 
concentrations. The x-axis is as described in panel (c). Mean and standard deviation are depicted. (e–f) VCD 
and viability measurements of cells treated either with solvent (0.1% v/v DMSO) or with tunicamycin (2.5 or 
10 μ g/mL) for 24 h. White and grey bars denote the NucleoCounter and 96-well-based cell-counting assay, 
respectively. Mean and standard deviation are depicted.
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is recommended. The observed dynamic linear ranges of the NucleoCounter NC-200 Cell Counter and the 
96-well-based cell-counting assay were 1 × 105–5 × 106 and 1 × 105–1 × 107 viable cells/mL, respectively 
(Fig. 2a–c). Intra-assay variation of VCD measurements was generally lower in the 96-well-based assay than in the 
NucleoCounter assay (Fig. 2c). Moreover, viability measurements were consistent between the two assays (Fig. 2d).
Next, we wanted to compare the performance of the two cell-counting assays with stressed cells. To this end, 
we treated CHO-S cells with the endoplasmic reticulum (ER)-stress inducer tunicamycin at two different concen-
trations for 24 h, because induction of ER stress affects the viability of mammalian cells29. Although lower viability 
values of the tunicamycin-treated cells were obtained in the 96-well-based assay compared with the NucleoCounter 
assay (Fig. 2e), VCD measurements of the two assays were consistent (Fig. 2f). Overall, the performance of the 
96-well-based cell-counting assay was satisfactory and we concluded that it was suitable for monitoring cell growth 
in the 96-well format.
Similar cell growth profiles and volumetric productivity in half-deepwells and shake 
flasks. Having established a 96-well-based cell-counting assay, we were able to analyse cell growth in all wells 
in a 96-HDW-microplate and compare cell growth with standard Erlenmeyer shake flasks. Cells were seeded at 
3 × 105 viable cells/mL and VCD and viability were measured daily for four days. Cell growth profiles in shake 
flasks and in wells in a 96-HDW-microplate were comparable (Fig. 3a). Viability during the four days of culture 
was in general high (> 95%) and was consistent between shake flasks and HDWs (Fig. 3a).
Variation of VCD measurements was in general low (coefficient of variation [CV] = 5–8%) during the four-day 
period (Fig. 3b). Therefore, the observed variation seems to originate from small differences in seeding density 
(Fig. 3b) and variation of the 96-well-based cell-counting assay (Fig. 2c). More importantly, the CV of doubling 
time was 3.7% from day 0–3 (Fig. 3c) demonstrating low well-to-well variation. Moreover, well position had no 
observed effect on cell growth rate (Supplementary Tables S7 and S8).
Next, we wanted to compare volumetric productivity of different therapeutic glycoproteins in HDWs and shake 
flasks. To this end, we chose our two model proteins hα 1AT and hC1INH as well as hEPO30 and Rituximab31. Two 
days after transfection, supernatant samples were obtained and product titer was determined. In general, volu-
metric productivity of each of the four proteins was comparable in HDWs and shake flasks (Fig. 3d–g). Titer of 
hα 1AT, Rituximab and hC1INH was on average 4%, 5% and 14% lower, respectively, in HDWs compared to shake 
flasks, whereas hEPO was 16% higher. Because we were able to demonstrate comparable cell growth profiles and 
volumetric productivity between shake flasks and HDWs, we inferred that the 96-HDW-microplate was a suitable 
small-scale cultivation vessel for use in our transient transfection-based screening platform.
Comparison of S11 variants fused N- and C-terminally to model proteins. We wanted to investigate 
the applicability of using split-GFP methodology to determine product titer because this is a potentially versatile 
alternative to antibody-based product titer assays for non-mAbs (see Discussion). To this end, we tagged our two 
non-mAb model proteins (hα 1AT and hC1INH) N- and C-terminally with two different variants of the split-GFP 
S11-tag: M3 and H7 (Supplementary Fig. S1a). The H7 variant has been shown to improve expression levels of 
membrane proteins in E. coli compared with the M3 variant32. The H7 variant (17 residues) is one amino acid 
residue longer than the M3 variant and contains seven histidine residues in contrast to the two histidine residues 
of M3 (Supplementary Fig. S2).
All hα 1AT and hC1INH variants were expressed transiently for two days. The H7 variant seemed to increase the 
titer of hα 1AT, whereas productivity of hα 1AT appeared unaffected by the M3 variant (Fig. 4a). In contrast, both 
variants gave rise to decreased titer of hC1INH (Fig. 4b) indicating that the effects of S11-fusion are protein-specific. 
C-terminally tagged hC1INH variants migrated slightly slower than untagged hC1INH consistent with fusion of 
the S11-tag, which is approximately 2 kDa in size (Fig. 4b). However, the N-terminally tagged hC1INH variants 
reproducibly migrated even slower than the C-terminally tagged hC1INH variants (Fig. 4b). This gel migration 
pattern was retained upon removal of N-glycans by PNGase F (Fig. 4c). However, removal of N- and O-glycans 
gave rise to co-migration of the N-terminally tagged M3 variant with the C-terminally tagged variants (Fig. 4d). 
Removal of N- and O-glycans also gave rise to a notable migration shift for the N-terminally tagged H7 variant 
but this variant reproducibly migrated slightly slower than the other three S11-tagged variants. The glycosidase 
mix used in this analysis is not able to remove all possible O-glycan structures. Thus, the N-terminally tagged H7 
variant might contain such resistant O-glycan structure(s). We concluded that O-glycosylation was affected when 
the S11 peptide was N-terminally fused to hC1INH. Apart from this, all S11-tagged variants of hα 1AT and the 
C-terminally tagged variants of hC1INH appeared as expected; migrating slightly slower than the untagged variants 
consistent with fusion of the S11-tag (Fig. 4a,b).
Preliminary results indicated that the H7 variant gave rise to lower fluorescence complementation intensity 
than the M3 variant upon split-GFP complementation (data not shown). In order to elucidate this, we compared 
signal-to-noise ratios of all S11 constructs. All M3 variants gave rise to higher signal-to-noise ratio than the H7 var-
iants (Fig. 4e,f), despite their titers being similar or lower (Fig. 4a,b). This suggests that the M3 variants have higher 
complementation capacity: thus, we chose this S11-tag variant for further experiments. We chose N-terminally 
tagged hα 1AT and C-terminally tagged hC1INH for all further experiments.
To determine the dynamic linear range of the split-GFP assay, we subjected a dilution series of a synthetic 
S11_M3 peptide to split-GFP product titer assay. Consistent with previously reported data11, we observed a clear 
linear relationship between split-GFP complementation intensity and peptide concentration (Fig. 4g). The dynamic 
linear range spanned two orders of magnitude and showed intra-assay variation below 10% (Fig. 4h). This suggests 
that substantial changes in titer can be quantified without additional dilution steps.
Split-GFP-based overexpression platform reveals target gene-specific effects on productivity. 
Having all required techniques established, we wanted to test the applicability of our screening platform. As proof 
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of concept, we tested seven target genes encoding proteins with previously reported effects on the productivity of 
recombinant glycoproteins in CHO cells (for reviews see7,9): five genes with positive effects (Xbp1s, Pdia3, Ppp1r15a, 
Ero1l, and Atf4) and two genes with mixed effects (Hspa5 and P4hb). Although not previously tested, Hsp90b1 was 
also included because its expression has been found to positively correlate with heterologous protein production33. 
The functions of the proteins encoded by these eight genes are all related to the ER, as they are either involved in 
the unfolded protein response or are chaperones and/or oxidoreductases localized in the ER. As negative controls, 
two pro-apoptotic genes were included: Bak1 and Bax34.
Eight individual transfection pre-mixes were made per target gene because we observed some transfection-based 
variation (Supplementary Fig. S3). Although not separated in time, data from individual transfections were pro-
cessed statistically as individual data points in order to cover as much variation as possible.
Co-expression of Atf4 gave rise to increased qp and titer of hα 1AT-S11 three days post-transfection (Fig. 5a,b). 
As for hC1INH-S11, co-expression of Xbp1s gave rise to increased qp and titer (Fig. 5c,d). Although less prominent, 
effects of Atf4 and Xbp1s were also observed two days post-transfection (Supplementary Fig. S4). Interestingly, 
three of the five genes previously reported to have a positive effect on specific productivity had a negative effect 
on both model proteins (Fig. 5a–d): Pdia3, Ppp1r15a, and Ero1l. Apart from reduced viability for Ppp1r15a, only 
Figure 3. Shake-flask-like cell growth profile and volumetric productivity in a 96-HDW-microplate.  
(a–c) Comparison of cell growth in shake flasks (three flasks) and HDW-microplate (96 wells). CHO-S cells 
were seeded at 3 × 105 cells/mL in shake flasks (25 mL in 125 mL flasks) or in HDWs (250 μ L) and VCD and 
viability were measured daily (day 0–4). (a) VCD (solid lines) and viability (dashed lines) versus culture 
time. Red and black lines show data from shake flasks and HDWs, respectively. VCD values are plotted on a 
logarithmic scale. (b) Coefficient of variation (CV) of VCD measurements in HDWs during the four days of 
culture. (c) Doubling time from day 0–3 in 96 wells calculated by exponential growth equation (least squares fit) 
in GraphPad Prism (GraphPad Software). Median and interquartile range are depicted and CV is shown above 
the data points. (d–g) Comparison of volumetric productivity in shake flasks and HDWs of hα 1AT, hEPO, 
Rituximab and hC1INH. CHO-S cells were transiently transfected with plasmids encoding the aforementioned 
proteins and supernatants two days post-transfection were obtained and titers were determined by ELISA 
(hα 1AT, hEPO and hC1INH) and bio-layer interferometry (Rituximab). 16 and 4 separate transfections were 
performed in HDWs and flasks, respectively. Mean, standard deviation, and percentage difference are shown.
www.nature.com/scientificreports/
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Figure 4. Analysis of split-GFP S11-tag variants. (a–f) CHO-S cells in 6-well plates were transfected with 
plasmids encoding hα 1AT or hC1INH either S11_M3 or S11_H7-tagged at the N- or C-terminus or untagged. 
Supernatants two days post-transfection were analyzed. (a) α -hα 1AT and (b–d) α -hC1INH Western blots 
under reducing conditions. The Western blots shown are representative of three experiments. (c,d) Proteins in 
supernatants were subjected to PNGase F and O-glycosidase (Protein Deglycosylation Mix) treatment under 
denaturing conditions where indicated. (e,f) Supernatants were analyzed by split-GFP product titer assay. 
Signal-to-noise (S/N) ratio was determined by defining noise as split-GFP complementation signal from mock 
transfected cells. Mean and standard deviation are depicted (n = 3). (g) A dilution series of a synthetic S11_M3 
peptide was analyzed by split-GFP product titer assay. The trend line from linear regression and correlation 
coefficient (R2) are shown. The encircled data point was found to be an outlier in the linear regression analysis. 
Mean and standard deviation from eight technical replicates are depicted. (h) Intra-assay variation of the split-
GFP product titer assay was analyzed from the data shown in panel (e). The coefficient of variation (CV) at 
different concentrations of the S11_M3 peptide are shown. The two-headed arrow denotes the defined dynamic 
linear range with low intra-assay variation (CV < 10%).
www.nature.com/scientificreports/
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slight differences in viability (Supplementary Fig. S5) and IVCD (Supplementary Fig. S6) were observed. Minute 
amounts of hα 1AT-S11 and hC1INH-S11 were produced upon co-expression of Bax and Bak1 (Fig. 5a–d). As 
expected from these pro-apoptotic genes, a significant drop in viability was observed (Supplementary Fig. S5) 
resulting in a drop in IVCD (Supplementary Fig. S6).
In order to validate the split-GFP product titer assay for our two model proteins, we wanted to compare this 
assay with the widely used protein quantification method; ELISA. To this end, product titer was determined in 
selected hα 1AT and hC1INH supernatant samples by ELISA (Fig. 5e,f). Relative titer determined by split-GFP 
complementation for hα 1AT-S11 and hC1INH-S11 was within ± 4% compared to ELISA. Thus, we concluded that 
the split-GFP product assay is able to accurately quantify relative titers of therapeutic glycoproteins in complex 
samples (spent media).
Positive effects of Atf4 and Xbp1s validated on untagged model proteins. Lastly, we wanted to test 
whether the positive effects of Atf4 and Xbp1s could be detected on untagged hα 1AT and hC1INH. To this end, 
untagged hα 1AT and hC1INH were expressed in CHO-S cells in a 96-HDW-microplate for three days with and 
without co-expression of Atf4 and Xbp1s. Titer and qp for untagged hα 1AT and hC1INH co-expressed with a mock 
plasmid were 72 mg/L and 13 pcd, and 3.2 mg/L and 0.5 pcd, respectively. Increased titer and qp were observed for 
hα 1AT and hC1INH upon co-expression of Atf4 and Xbp1s, respectively (Fig. 6a,b). Although the effects were 
8–16% higher with S11-tagged than untagged model proteins (Supplementary Table S9), we concluded that our 
split-GFP-based transient expression platform is able to identify effects on productivity of non-mAb glycoproteins.
Discussion
Compared with conventional shake flask cultivation of CHO cells, cultivation in 96-well microplates signifi-
cantly increases throughput. Originally, growth conditions in 96-well microplates were suboptimal due, for 
example, to excessive evaporation and insufficient oxygen transfer rate35. However, these issues have been solved 
by Duetz covers36, which reduce evaporation while allowing sufficient oxygen transfer. The dramatic effect of 
the Duetz cover on evaporation was recently demonstrated by showing a 5.5-fold decrease in evaporation com-
pared with gas-permeable seals37. In the present study, evaporation of 1.4% v/v per well per day was observed in 
96-HDW-microplates with Duetz covers (data not shown). We were able to demonstrate cell-growth profiles in 
Figure 5. Co-expression of target genes affects split-GFP-based specific and volumetric productivity 
of hα1AT-S11 and hC1INH-S11. (a,b) Plasmid encoding hα 1AT N-terminally tagged with S11_M3 was 
co-transfected with mock plasmid or plasmids encoding target (mouse) genes into CHO-S cells in 96-HDW-
microplates. Three days after transfection, supernatants were obtained and subjected to split-GFP product 
titer assay for determination of relative titer. Split-GFP-based specific productivity (qp) and titer are shown. 
Eight separate transfections were performed in each experiment and experiments were performed twice 
(n = 2; 16 wells). Mean and standard deviation are depicted. Only statistically significant (p ≤ 0.05) increases 
in productivity are shown. (c,d) As described for panels (a,b), with the only difference being use of plasmid 
encoding hC1INH C-terminally tagged with S11_M3 instead of plasmid encoding hα 1AT. (e,f) Comparison 
of split-GFP-based product titer assay and ELISA. hα 1AT (mock and Atf4 ) and hC1INH (Mock and Xbp1s) 
supernatants described in panels a-d were subjected to ELISA for determination of hα 1AT and hC1INH titers. 
Mean, standard deviation and percentage difference are shown.
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96-well microplates that were comparable to those in shake flasks (Fig. 3a). Similarly, shake-flask-like cell-growth 
profiles have been reported in 24-well plates using Duetz covers38. The well-to-well variation of VCD on day 4 
in 24-well plates was reported to be 9.0%38, which is comparable with the value of 7.5% observed in 96-well 
microplates in this study (Fig. 3b). No effect of well position on cell growth rate was observed in 24-well plates, 
which is consistent with our results in 96-well microplates (Supplementary Table S7).
Similarly, we observed relatively low variation of titer and qp (Figs 5 and 6). Mean variation of titer and 
qp was 9.7% and 14.9%, respectively, for both model proteins and all target genes except Bak1 and Bax (data 
from Fig. 5). The variation of qp is consistent with the previously reported variation of qantibody (16%) from 
polyethylenimine-mediated transfection of CHO cells in flasks10. The variation of titer is comparable with the 
observed variation (CV: 9.2%) in transfection efficiency, which ranged from 55% to 80% (Supplementary Fig. S3). 
This range likely explains why unexpectedly low titers and qp were observed for some wells (e.g. Ero1l and Hsp90b1 
in Fig. 5a,b and Atf4 in Fig. 6a). To our knowledge, this is the first published example of transient protein production 
in CHO cells cultivated in 96-well microplates. Recently, a study was published on transient expression of IgG1 
in HEK293 cells by polyethylenimine-mediated transfection in 96-deepwell microplates using Duetz covers37. 
Unfortunately, comparison of well-to-well variation from that study is not possible, because only plate-to-plate 
variation was reported. Importantly, we were able to show that volumetric productivity of four different therapeutic 
glycoproteins in shake flasks was comparable in HDWs (Fig. 3d–g). However, some differences were observed 
ranging from − 16% to + 14% between shake flasks and HDWs. Moreover, variation in titer was higher in HDWs 
compared to shake flasks: average CV of all four proteins HDWs and shake flasks was 7% and 4%, respectively. 
Overall, it is likely that these differences partly arise from differences in the transfection procedure. Complexation 
of the transfection reagent and plasmids is a time-dependent process39 and the complex incubation time likely 
varies more when transfecting cells in HDWs compared to shake flasks. Automation of the transfection process 
by a liquid handling robot could potentially minimize this variation to some extent.
Sixteen wells per gene were used in the screening platform. The sample size can be reduced to three and six wells 
to detect fold-changes of 1.5 to 1.3, respectively, with power of 0.80 and type I error of 0.05 based on the observed 
variation of 15%. Moreover, several plates can be analysed in parallel. Finally, the screening platform is suitable 
for automation by a liquid handling robot because the majority of the experimental work involves liquid transfer 
between 96-well microplates. These options have the potential to increase the throughput and number of identified 
positive effects significantly of the screening platform. Importantly, positive effects on productivity of target genes 
must eventually be further characterized in an industry-like context as well as product quality attributes such as 
glycosylation and bioactivity.
Effects on productivity were less pronounced on untagged model proteins than S11-tagged model proteins 
(Supplementary Table S9). This discrepancy is likely a consequence of fusing the S11-tag to the model proteins. 
Although the S11-tag is relatively small (~2 kDa), fusion of this tag to proteins could change the overall confor-
mation as well as post-translational modifications. Indeed, the H7 S11-variants of hα 1AT led to increased titers 
and all S11-tagged variants of hC1INH gave rise to decreased titers compared to untagged protein (Fig. 4a,b). 
Moreover, N-terminally fusion of the S11 tag to hC1INH altered O-glycosylation (Fig. 4c,d). These results clearly 
show that fusion of the S11-tag to the protein of interest is a possible drawback of this platform. However, further 
optimization of the S11-tag sequence might be able to address this issue to some extent – for example by altering 
the glycine-serine linker sequence40. Despite the effects of the S11-tag on titers and post-translational modifications, 
Figure 6. Positive effects of target genes on productivity validated on untagged hα1AT and hC1INH. 
(a) Plasmid encoding untagged hα 1AT was co-transfected with a mock plasmid or plasmid encoding Atf4 
into CHO-S cells in a 96-HDW-microplate. Three days after transfection, supernatants were obtained and 
hα 1AT titer determined by ELISA. Normalized titer and specific productivity (qp) are shown. Eight separate 
transfections were performed in each experiment and experiments were performed twice (n = 2; 16 wells). 
Mean, standard deviation, and statistically significant (p ≤ 0.05) fold-changes are depicted. (b) Plasmid 
encoding untagged hC1INH was co-transfected with mock plasmid or plasmid encoding Xbp1s into CHO-S 
cells in 96-HDW-microplate. Three days after transfection, supernatants were obtained and hC1INH titer 
determined by ELISA. Normalized titer and specific productivity (qp) are shown. Eight separate transfections 
were performed in each experiment and experiments were performed twice (n = 2; 16 wells). Mean, standard 
deviation, and statistically significant (p ≤ 0.05) fold-changes are depicted.
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we could reproduce that Atf4 and Xbp1s overexpression significantly improved productivity of untagged hα 1AT 
and hC1INH, respectively (Fig. 6a,b). Moreover, relative titers obtained by ELISA and split-GFP complementa-
tion were consistent (Fig. 5e,f). Thus, split-GFP complementation seems to be a versatile antibody-independent 
method for determining relative product titer of recombinant glycoproteins produced in CHO cells. For mAbs, 
several well-established high-throughput and automatable product titer assays exist. However, this is not the case 
for the majority of non-mAbs; split-GFP-based product titer determination therefore seems particularly valuable 
for non-mAb recombinant proteins. Besides the application as a discovery tool in the platform presented here, the 
split-GFP methodology could be useful in initial trials of producing protein variants by transient expression in 
the biopharmaceutical industry. However, the split-GFP system is not suitable for larger scale production in stable 
cell lines, because the S11-tag eventually becomes an undesired trait in for example detailed characterization of 
the protein and in clinical trials.
Five genes previously reported to have positive effects on productivity of recombinant glycoproteins in CHO cells 
were studied: Atf4, Xbp1s, Pdia3, Ppp1r15a, and Ero1l. Atf4 and Xbp1s increased productivity in a product-specific 
manner (Fig. 5). It is unclear whether this is because of product specificity, due to a possible difference in baseline qp 
of hα 1AT and hC1INH, or a combination thereof. In contrast, Pdia3, Ppp1r15a, and Ero1l did not increase produc-
tivity in the present study (Fig. 5). There are several plausible reasons for this, which are discussed here: (1) Effects 
of target genes are model protein-specific. Owing to the interchangeable and parallelisable setup of the screening 
platform, model protein-specific effects can readily be studied by testing different model proteins (2) Expression 
levels of target genes affect productivity. Dose-dependence of target genes can be studied in a high-throughput 
manner by titrating the target gene-encoding plasmid with non-specific (filler) plasmid6,41,42. (3) qp may be too 
low in transient expression setups for rate-limiting steps to form in the secretory pathway similar to those observed in 
highly gene-amplified stable clones. Relatively high transfection efficiency was obtained (Supplementary Fig. S3); 
consequently, substantial increase in qp may be difficult to obtain by optimizing the current transfection setup. 
Alternatively, episomal replication-proficient CHO cell lines43,44 or stable CHO cell pools using the piggyBac 
transposon system45 could be used to increase and sustain productivity. (4) Mouse-derived genes may not be 
functional in CHO cells. Although mouse and hamster are closely related animals in an evolutionary context, 
proteins encoded from mouse genes might not be fully functional in CHO cells due to for example altered codon 
usage and post-translational modifications. Moreover, favourable interactions might not be compatible between 
a mouse gene-encoded protein and a human therapeutic glycoprotein in CHO cells. While not all mouse genes 
may be appropriate for expression in CHO cells, mouse genes have previously been used successfully to improve 
productivity of recombinant glycoproteins in CHO cells46,47. Furthermore, both pro-apoptotic genes (Bak1 and 
Bax) clearly affected cell viability (Supplementary Fig. S5). Alternatively, mouse genes can be replaced by homol-
ogous hamster genes owing to the recent drafts of the Chinese hamster and CHO cell line genomes48–51. However, 
not all hamster genes are at present annotated correctly when compared to mouse homologues (our unpublished 
observations). Consequently, using hamster genes in our screening platform could lead to erroneous conclusions, 
until sequencing and annotation of the hamster genome have been further refined.
Combinatorial cell line engineering seems to be a constructive way of improving secretory capacity and several 
examples of synergistic effects on productivity of co-expressing two target genes have been reported52–54. More than 
20,000 genes are present in the Chinese hamster genome49 and combinatorial approaches dramatically increase 
the number of conditions possible to be tested. Compared with current lower throughput setups, our platform 
facilitates cost-efficient combinatorial screening of genes. In conclusion, we believe that our target gene-screening 
platform holds the potential to unravel novel genes and combinations of genes that can enhance the secretory 
pathway machinery in CHO cells.
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